Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study by unknown
Jensterle et al. Journal of Ovarian Research  (2015) 8:32 
DOI 10.1186/s13048-015-0161-3RESEARCH Open AccessShort term monotherapy with GLP-1 receptor
agonist liraglutide or PDE 4 inhibitor roflumilast
is superior to metformin in weight loss in obese
PCOS women: a pilot randomized study
Mojca Jensterle1, Vesna Salamun2, Tomaz Kocjan1, Eda Vrtacnik Bokal2 and Andrej Janez1*Abstract
Objective: To evaluate whether liraglutide or roflumilast significantly affects body weight when compared to
metformin in obese women with PCOS.
Design/main outcome measure: A 12-week prospective randomized open-label study was conducted with 45
obese women with PCOS diagnosed by the ASRM-ESHRE Rotterdam criteria. They were randomized to metformin
(MET) 1000 mg BID or liraglutide (LIRA) 1.2 mg QD s.c. or roflumilast (ROF) 500 mcg QD. The primary outcome was
change in measures of obesity.
Results: Forty-one patients (aged 30.7 ± 7.9 years, BMI 38.6 ± 6.0 kg/m2, mean ± SD) completed the study. Subjects
treated with LIRA lost on average 3.1 ± 3.5 kg (p = 0.006), on ROF 2.1 ± 2.0 kg (p = 0.002) vs. 0.2 ± 1.83 kg in MET
group. BMI decreased for 1.1 ± 1.26 kg/m2 in LIRA (p = 0.006), for 0.8 ± 0.99 kg/m2 in ROF (p = 0.001) vs. 0.1 ±
0.67 kg/m2 in MET. LIRA was superior to MET in reducing weight (p = 0.022), BMI (p = 0.020), waist circumference
(p = 0.007). LIRA also resulted in decrease in VAT area (p = 0.015) and more favorable dynamics in glucose
homeostasis during OGTT. ROF resulted in reduction of waist circumference (p = 0.023). In addition, ROF led to
testosterone reduction (p = 0.05) and increase in menstrual frequencies (p = 0.009) when compared to baseline.
Conclusion: Short-term monotherapy with liraglutide or roflumilast was associated with significant weight loss in
obese PCOS. Liraglutide was superior to metformin, whereas roflumilast resulted in greater, yet not statistically
significant, mean weight loss when compared to metformin. Reduction of body weight with liraglutide resulted in
improvement of body composition.
Trial registration: ClinicalTrials.gov NCT02187250.
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Obesity is frequently present in women with polycystic
ovary syndrome (PCOS) and aggravates the adverse fea-
tures of the syndrome [1]. In overweight and obese pa-
tients with PCOS, lifestyle changes represent first-line
treatment [2]. However, weight loss is frequently unsatis-
factory with lifestyle changes alone or in combination with
metformin and many women eventually regain weight [3].* Correspondence: andrej.janez@kclj.si
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stated.In these women, the combination of lifestyle changes with
identification of new effective and safe treatment options
for weight reduction could be considered.
Pharmacological interventions on incretin system are a
novel treatment of type 2 diabetes and proved valuable for
weight loss in other obese populations [4]. In addition,
obese women with PCOS who have not responded to life-
style modification and metformin benefit from 12 week
treatment with long-acting glucagon-like peptide (GLP)—1
receptor agonist liraglutide as an add-on therapy to met-
formin [5]. Experiences with the use of GLP-1 receptor
agonist regarding weight loss as a primary outcome inarticle distributed under the terms of the Creative Commons Attribution
s/by/4.0), which permits unrestricted use, distribution, and reproduction in any
rly credited. The Creative Commons Public Domain Dedication waiver
ero/1.0/) applies to the data made available in this article, unless otherwise
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GLP-1 as a multi-targeting regulator of food intake has
been recognized also in this population [6].
Less recognized distinct regulatory mechanisms re-
lated to the enhancement of GLP-1 mediated action
through the inhibition of phosphodiesterase enzymes
(PDE) 4 has recently became a reasonable focus of a po-
tential new anti-obesity management. Roflumilast, the
first drug specifically targeting PDE4, is well recognized
as efficient treatment of chronic inflammatory diseases,
primarily chronic obstructive pulmonary disease (COPD)
[7, 8]. In addition, the use of roflumilast has shown posi-
tive metabolic effects on glucose homeostasis and weight
reduction in newly diagnosed type 2 diabetes mellitus
(T2DM) [9]. Furthermore, combined therapy of roflumi-
last and metformin significantly reduced body weight in
obese PCOS when compared to metformin, primarily
due to a loss of fat mass [10]. The observed beneficial
metabolic outcomes of selective PDE4 inhibition by
roflumilast are based on the interplay between the PDE4
and the regulation of GLP-1 [11].
No previous studies to date compared the effect of
long acting GLP-1 receptor agonist liraglutide and se-
lective PDE4 inhibitor roflumilast that is involved in
GLP-1 release on body weight either in PCOS or any
other obese population. The aim of this pilot study was
to evaluate whether the monotherapy with liraglutide or
roflumilast significantly affects body weight when com-
pared to metformin in obese women with PCOS.




The study consists of a 12-week prospective randomized
open-label design conducted with 45 obese women with
PCOS diagnosed by ASRM-ESHRE Rotterdam criteria.
All subjects had type A phenotype of PCOS including
concomitant presence of a) hyperandrogenemia on ei-
ther the biochemical or the clinical level, b) menses ab-
normalities and c) PCO morphology. They were eligible
for enrollment if they were aged 18 years to menopause
and obese (body mass index: BMI ≥ 30). Exclusion
criteria was history of carcinoma or neuropsychiatric
events, personal or familiar history of multiple endocrine
neoplasia 2, significant cardiovascular, kidney or hepatic
disease and the use of medications known to affect re-
productive or metabolic functions within 180 days prior
to study entry. Some of them were using oral contracep-
tives advised by their gynecologists more than 6 month
before being recruited.
They were randomized to one of the three treatment
arms: metformin (MET) 1000 mg BID or liraglutide
(LIRA) 1.2 mg QD s.c. or roflumilast (ROF) 500 mcgQD. Liraglutide was initiated at a dose of 0.6 mg injected
s.c. once per day and increased to 1.2 mg/day after
1 week. Metformin was initiated at a dose of 500 mg
once per day and increased by 500 mg every 3 days up
to 1000 mg BID. Patients on liraglutide were provided
with glucose-monitoring devices and supplies and edu-
cated on their use. They were instructed to measure
blood glucose levels at any signs and symptoms suggesting
low blood glucose. Hypoglycemia was defined according
to American Diabetes Association criteria as symptoms
suggestive of low blood glucose confirmed by self-
monitored blood glucose measurement below 3.9 mmol/l
[12]. All women were instructed to report any side effects
during the treatment. They were given a general advice on
lifestyle intervention. A diet of 500–800 kcal/day reduc-
tion made up of 50 % carbohydrates, 20 % proteins and
30 % of fat with increased consumption of fiber, whole
grains, cereals, fruits and vegetables along with at least
30 min of moderate intensity physical activity daily had
been recommended to all women at the beginning of the
study. During the study lifestyle intervention was not
again actively promoted.
The primary outcome of the study was mean change in
measures of obesity. Secondary outcomes included hor-
monal and metabolic changes. Post randomization and at
study endpoint all patients underwent standard anthropo-
metric measurements: height, weight, waist circumference,
blood pressure, measurement of whole-body composition
by a Hologic Dual Energy X-ray Absorptiometer (DXA),
including visceral adipose tissue (VAT) area. BMI was cal-
culated as the weight in kilograms divided by square of
height in meters. Before randomization transvaginal ultra-
sound scans of the ovaries was performed by an experi-
enced sonographer. The presence of PCO morphology
was diagnosed by the presence of 12 or more follicles in
each ovary measuring 2–9 mm in diameter and/or in-
creased ovarian volume (>10 cm3).
A fasting blood was drawn for determination of glucose,
insulin, luteinizing hormone (LH), follicle stimulating hor-
mone (FSH), androstenedione, dehydroepiandrosterone
sulphate (DHEAS), total and free testosterone (T) followed
by a standard 75 g oral glucose tolerance test (OGTT) to
assess glucose homeostasis. Glucose levels were determined
using a standard glucose oxidase method (Beckman Coulter
Glucose Analyzer, Beckman Coulter Inc CA, USA). Insulin
was determined by immunoradiometric assay (Biosource
Europe S.A., Nivelles, Belgium). LH and FSH were deter-
mined using an immunometric assay (Diagnostic Products
Corporation, LA). Androstenedione and DHEAS were
measured by specific double antibody RIA using 125
I-labeled hormones (Diagnostic Systems Laboratories,
Webster, Tx). Total and free testosterone levels were mea-
sured by coated tube RIA (DiaSorin, S. p. A, Salluggia, Italy
and Diagnostic Products Corporation, LA, respectively).
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with a chemiluminescent immunoassay (Immulite 2000
Analyzer, Siemens Healthcare, Erlangen, Germany).
Intraassay variations ranged from 1.6 to 6.3 %, and interas-
say variations ranged from 5.8 to 9.6 % for the applied
methods. Pre- and posttreatment samples from each pa-
tient were assayed in the same assay run.
Homeostasis model assessment (HOMA-IR) calculation
was applied as a measure for insulin resistance (IR). Safety
clinical assessment was performed at the beginning and
week 4, 8 and 12 of the treatment period. Pregnancy was
excluded by measuring β-human chorionic gonadotropin.
Its measurement was repeated during the study whenever
pregnancy was clinically possible. Women were advised to
strictly use barrier contraception.
Study approval
The study was approved by a National Medical Ethics
Committee and conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guide-
lines. Informed consent was obtained from all patients
before participation.
Statistical analysis
The primary endpoint of this study, for which a power cal-
culation was used to determine the sample size, was mean
change in weight. We based our calculations on a previous
study with comparative treatment intervention [4]. It was
determined that 12 patients would be needed per group in
order to give a power of 80 % for the detection of a statis-
tically significant difference (alpha = 0.05) of approxi-
mately 2.5 % in weight loss and estimated dropout rate of
15 %. The power estimate was performed with the online
calculator at http://hedwig.mgh.harvard.edu/sample_size/
size.html. A block randomization was used for subject as-
signment in random block sizes of 3, 6, and 9. A list of
random numbers was excel generated and each random
number corresponds with 1 of the 3 possible interventions
(MET, LIRA, ROF).
Results are presented as mean ± standard deviation
(SD). Normal data distribution was checked with the
Shapiro-Wilk test. Differences at baseline between the
treatment groups were checked with general linear
model. The differences between treatment groups were
checked and confirmed using ANOVA test. Treatment
impact on the primary outcome measure was analyzed
with evaluable patients data using repeated-measures
linear mixed effects model with time points (baseline,
12 weeks) and therapeutic groups (MET arm, LIRA arm,
ROF arm). Multiple testing of secondary outcomes was
not performed. P value of less than 0.05 was considered
statistically significant. Other than sample size calcula-
tion, all statistical analyses were performed using the
SPSS 17.0 Statistical Software Package.Results
Baseline results
The study enrolled 45 participants. Two MET treated
patient discontinued the study, one because of diarrhea,
one due to protocol violation, one LIRA treated because
of nausea and one ROF treated because of headache.
Forty-one patients (aged 30.7 ± 7.9 years, BMI 38.6 ±
6.0 kg/m2, mean ± SD) completed the study: 13 on MET,
14 on LIRA and 14 on ROF. There were no significant
differences at baseline in any of the parameters between
the treatment groups. Baseline characteristics of the
study outcomes are provided in Tables 1 and 2.Measures of obesity
Subjects treated with LIRA lost on average 3.1 ± 3.5 kg
(p = 0.006), on ROF 2.1 ± 2.0 kg (p = 0.002) vs 0.2 ±
1.83 kg weight loss in MET group (p = 0.735). BMI de-
creased for 1.1 ± 1.26 kg/m2 in LIRA (p = 0.006), for 0.8 ±
0.99 kg/m2 in ROF (p = 0.001) vs 0.1 ± 0.67 kg/m2 in MET
(p = 0.731). LIRA was superior to MET in reducing weight
(p = 0.022), BMI (p = 0.020) and waist circumference (p =
0.007). Roflumilast resulted in greater, yet not statistically
significant, mean weight loss when compared to metfor-
min (p = 0.203). Although the mean weight loss was
greater in the LIRA than in the ROF arm the difference
was not statistically significant (p = 0.992). LIRA resulted
in significant decrease in VAT area (p = 0.015). Both LIRA
and ROF were associated with waist circumference reduc-
tion when compared to baseline (p = 0.009 and p = 0.023,
respectively). The mean pre-and post-treatment measures
of obesity are presented in Table 1.Metabolic parameters
HOMA-IR decreased in all treatment arms, although the
between treatment difference was not statistically signifi-
cant yet. There was a statistically significant within-
treatment reduction from baseline to last visit in fasting
glucose levels and glucose at 30 (from 8.2 ± 2.4 to 7.7 ±
2.1 mmol/l, p = 0.028) and 120 min (from 6.7 ± 2.9 to
5.4 ± 1.9 mmol/l, p = 0.050) of OGTT in LIRA treated
women. Liraglutide was superior to metformin in redu-
cing glucose at 120 min of OGTT (p = 0.041). The mean
pre-and post-treatment values of fasting glucose, fasting
insulin and HOMA-IR are presented in Table 2.Endocrine parameters
At 12 weeks a significant total T and Free Androgen
Index (FAI) reduction were noted in ROF arm when
compared to baseline. No statistically significant differ-
ences were found in free T, SHBG, androstenedione,
DHEAS (Table 2), or in LH and FSH, neither over time
nor when analyzing it separately by therapeutic arm.
Table 1 Baseline and 12-week post-treatment measures of obesity
MET (n = 13) LIRA (n = 14) ROF (n = 14) P values
Baseline After therapy Baseline After therapy Baseline After therapy
Weight (kg) 108.3 ± 17.0 108.1 ± 17.5 102.8 ± 16.3 99.7 ± 17.2 111.1 ± 16.1 109.0 ± 16.4 T = 0.025 (L vs. M = 0.022); I (L = 0.006; R = 0.002)
BMI (kg/m2) 39.4 ± 6.9 39.3 ± 7.0 36.7 ± 5.6 35.6 ± 5.8 39.9 ± 5.4 39.1 ± 5.7 T = 0.023 (L vs. M = 0.020); I (L = 0.006; R = 0.001)
Waist circumference (cm) 120.5 ± 14.5 121.3 ± 13.2 115.7 ± 12.5 112.6 ± 12.9 123.0 ± 15.9 121.8 ± 16.1 T = 0.009 (L vs. M = 0.007); I (L = 0.009; R = 0.023)
VAT area (cm2) 131 ± 44.5 126.5 ± 48.3 160.3 ± 67.9 140.7 ± 60.8 157.3 ± 36.7 153.7 ± 21.9 I (L = 0.015)












Table 2 Baseline and 12-week post-treatment metabolic and endocrine parameters
MET (n = 13) LIRA (n = 14) ROF (n = 14) P values
Baseline After therapy Baseline After therapy Baseline After therapy
Glu 0 min OGTT (mmol/L) 4.8 ± 0.9 4.4 ± 1.6 5.1 ± 1.1 4.7 ± 0.7 5.1 ± 0.5 5.0 ± 0.4 I (L = 0.048)
Insulin 0 min OGTT (mU/L) 15.5 ± 6.0 12.7 ± 7.0 16 ± 9.3 14.5 ± 9.4 21.0 ± 7.7 21.0 ± 8.7 NS
HOMA-IR 3.3 ± 1.2 2.5 ± 1.9 3.8 ± 2.8 3.2 ± 2.4 4.5 ± 1.7 4.6 ± 2.1 NS
Total T (nmol/L) 1.7 ± 1.1 1.5 ± 1.2 1.7 ± 0.7 1.5 ± 0.6 1.8 ± 0.5 1.5 ± 0.6 I (R = 0.050)
Free T (nmol/L) 3.6 ± 2.6 4.3 ± 3.0 3.7 ± 2.0 3.2 ± 2.0 4.0 ± 2.2 4.0 ± 2.3 NS
SHBG (nmol/L) 28.6 ± 11.1 31.5 ± 5.6 30.5 ± 9.9 32.8 ± 14.2 27.0 ± 11.4 29.1 ± 12.1 NS
FAI 7.6 ± 8.0 4.8 ± 3.6 6.5 ± 3.7 5.4 ± 2.9 8.3 ± 5.9 6.1 ± 4.6 I (R = 0.016)
Androstenedione (nmol/L) 8.9 ± 3.8 10.7 ± 7.0 8.7 ± 3.4 9.0 ± 3.9 9.5 ± 2.5 9.4 ± 3.9 NS
DHEA-S (μmol/L) 5.9 ± 2.5 6.8 ± 3.5 6.6 ± 3.3 6.1 ± 2.4 5.6 ± 2.7 5.2 ± 1.9 NS
For p values, T = overall effect after all treatments, R = ROF, L = LIRA, M =MET, I = interaction differences between treatment over trials
NS not significant
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Menstrual frequency increased with all treatments. The
increase was shown as being slightly greater in patients
treated with ROF (from 0.57 ± 0.40 to 0.88 ± 0.20 per
month, p = 0.009), compared with MET (from 0.74 ±
0.30 to 0.92 ± 0.20 per month, p = 0.090) and LIRA (from
0.62 ± 0.30 to 0.74 ± 0.30, p = 0.165). However, the
between-treatment differences were not statistically sig-
nificant yet.
Adverse events
The most commonly reported adverse events in MET
group were diarrhea (4/14) and nausea (4/14) that re-
solved in the first week for 3/14 subjects and within
4 weeks of the study onset for the 1/14 woman. Adverse
events associated with LIRA were nausea (4/14), obstipa-
tion (2/14), diarrhea (1/14), headache (1/14) and insom-
nia (1/14). In the ROF group, 5/14 subjects had mild
gastrointestinal problems (nausea and diarrhea), 2/14
had mild headache and 1/14 reported mild depression in
the last month of the study. Nausea in LIRA arm was
present up to 3 days when liraglutide was initiated at a
dose of 0.6 mg injected s.c. once per day and if present
reappeared for 2 to 3 days when the dose was increased
to 1.2 mg/day after 1 week. It was not accompanied with
vomiting. Nausea in ROF arm was more persistent when
compared to MET yet it was mild and not accompanied
with vomiting. Some subjects in all treatment groups
had multiple side effects. No side effect was reported by
10/14 women in MET arm, 8/14 in LIRA arm and 8/14
in ROF arm. Hypoglycemic event was not reported in
any group. The injection regimen of LIRA did not im-
pair adherence or cause significant withdrawal over ROF
and MET during treatment.
Discussion
The comparison of long-acting GLP-1 receptor agonist
liraglutide or selective PDE4 inhibitor roflumilast versusmetformin on changes of measures of obesity have not yet
been evaluated in women with PCOS or any other obese
population. To our knowledge, this is the first study to date
demonstrating that in a short period of time liraglutide
was significantly more effective than metformin regarding
weight loss and improvement of body composition in
obese PCOS women. Roflumilast resulted in greater, yet
not statistically significant, mean weight loss when com-
pared to metformin. In addition, liraglutide treatment was
followed with within-treatment favorable improvements
in glucose homeostasis during OGTT and in significantly
greater reduction of glucose at 120 min of OGTT when
compared to metformin, while roflumilast resulted in tes-
tosterone reduction and increase in menstrual frequencies
when compared to baseline.
Liraglutide resulted in the between-treatment difference
of about 3 kg weight lost versus metformin. Although
metformin is still widely used in the management of
PCOS due to its observed curative and potentially pre-
ventive clinical benefits, including body weight reduction
and improvement of fat distribution, recent guidelines
developed by the Endocrine Society recommended its use
only in women with PCOS who are already undergoing
lifestyle treatment and do not have improvement in im-
paired glucose tolerance and in those who have normal
weight, but still have impaired glucose tolerance [13]. In
fact, its effect on weight reduction and fat distribution in
PCOS remains controversial. In accordance with our
study, most studies and meta-analysis concluded that as a
mono-therapy, metformin does not significantly reduce
body weight, although some studies have reported some
marginal benefit in longer observation period [14, 15].
Until today, only few studies have addressed the pos-
sible use of GLP-1 receptor agonists in women with
PCOS, but all with some important methodological limi-
tations regarding the evaluation of their effect on body
weight. We previously conducted a study with obese
PCOS women who had been pretreated with metformin
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with metformin before recruitment. In that study, one
group was kept on metformin for 12 more weeks while
comparing it for weight loss with other two groups
taking liraglutide alone or liraglutide in combination to
metformin. Patients on combined treatment lost on
average 6.5 kg compared with a 3.8 kg loss in LIRA
group, with the between-treatment difference of about 5
and 3 kg, respectively, when compared to metformin
mono-therapy [5]. The results are perfectly in line with
the findings of this study. However, the main issue of
our previous study was inclusion of non-responders for
the outcome of interest that could have brought bias
from the beginning. Apprised of that limitation the
present study was conducted with a much better and fair
design that included drug naïve patients. Furthermore,
an average weight reduction of 3.0 kg, yet achieved in a
longer period of observation and with larger dosage of
1.8 mg QD s.c., was observed also in a 24 week-study
that reported the potential impact of liraglutide on
markers of liver fibrosis in PCOS [16]. However, the
study was not designed to evaluate the change in
measures of obesity as a primary outcome of interest. As
opposed to long acting GLP-1 agonist liraglutide, the
only report using short acting GLP-1 agonist exenatide
in treatment-naive overweight patients with PCOS was a
24 week-study conducted to evaluate change in men-
strual frequency whereas change in body weight was
pre-specified as secondary outcome. Combined treat-
ment with exenatide and metformin was superior to exe-
natide and metformin mono-therapies resulting in an
average weight reduction of 6 kg in combined group
compared to 3.2 kg in the exenatide, and of 1.6 kg in
metformin group [17]. Weight reduction in our study is of
comparable magnitude to the exenatide group, but
achieved in a shorter period of time. In addition, we ob-
served small drop out in our study as opposed to relatively
large drop out in the study with exenatide, which was
probably conditioned by the choice of GLP-1 receptor
agonist. It has been demonstrated in individuals with type
2 diabetes mellitus that liraglutide caused less adverse
events and therapy discontinuation than exenatide [18].
Contrary to liraglutide acting as a GLP-1 receptor
agonist, selective PDE4 inhibitor roflumilast interacts to
GLP- mediated effect through completely different path-
ways. It is involved in the PDE4 regulation of signaling
cascades linked to GLP-1 release. In rodent model roflu-
milast enhanced plasma GLP-1 levels up to 2.5 –fold
[11]. In clinical studies, roflumilast was associated with
a weight decrease of about 2 kg versus placebo in
12 months in patients with chronic obstructive pulmon-
ary disease (COPD) [7, 8] and with mean weight change
of about 2 kg in 12 weeks versus placebo in patients with
newly diagnosed type 2 diabetes mellitus without COPD[9]. We recently reported that in obese women with
PCOS, roflumilast added to metformin was superior to
metformin alone in reducing mean body weight after
12 weeks, with the between treatment difference of
about 5 kg [10]. Referring to the patients’ history on pre-
treatment with metformin we were cautioned that the
study did not have a proper control to draw definitive
conclusions solely about the effects of roflumilast in
PCOS. Considering the innovative concept that grasps
selective PDE4 inhibition as a potential new therapeutic
target in obesity associated populations, in the present
study we used an upgraded design to further elucidate
the potential effect of roflumilast in treatment-naïve
obese PCOS population. Treatment with roflumilast re-
sulted in the between-treatment difference of about 2 kg
weight lost versus metformin, which is in accordance
with the study of the same observational period in pa-
tients with newly diagnosed type 2 diabetes mellitus [9].
However, the weight reduction with both liraglutide and
roflumilast in the present study was of lesser magnitude
when compared to the studies in PCOS population using
combined therapies, including combined treatment of
GLP-1 receptor agonist [5, 17] and metformin or com-
bination of roflumilast and metformin [10], which might
suggest a possible additive role of metformin to GLP-1
mediated effect [19, 20].
Furthermore, the results of this study indicate that lira-
glutide was superior to roflumilast regarding improve-
ments of measures of obesity and metabolic profile, not
being demonstrated with roflumilast. Previously, effects of
roflumilast on glucose metabolism has been studied in a
12 week, randomized, double blind, placebo controlled
study of patients with newly diagnosed type 2 diabetes
mellitus without COPD. Over 12 weeks, HbA1C levels
declined substantially in the roflumilast group compared
with placebo [9]. The beneficial impact of roflumilast on
metabolic parameters has been explained by the same
mechanisms mediated through its elevating effect on the
GLP-1 incretin hormone levels as being hypothesized to
be responsible for its effect on body weight reduction [9].
No study to date directly compared these two therapies
and we might only reasonably speculate that the direct en-
hancement of GLP-1 axis with GLP-1 receptor agonists is
more potent than GLP-mediated effect through PDE4
regulation. However, this was a pilot study, not powered
for all possible relevant metabolic outcomes, but powered
specifically for weight loss.
Surprisingly, despite the superiority of liraglutide in
weight reduction and glucose homeostasis, roflumilast
resulted in total testosterone and FAI reduction and in-
crease in menstrual frequencies not being demonstrated
in liraglutide arm. These observed beneficial trends that
obviously went beyond weight reduction effect might be
related to the expression of PDE4 enzymes in ovaries
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esis. A potential role of roflumilast in direct regulation
of ovarian steroidogenesis and in the pathophysiology of
PCOS could not be excluded [21, 22]. The improvement
of androgen profile tended to be slightly greater also in
PCOS patients treated with roflumilast added to metfor-
min in our previous study [10]. Clearly, due to generally
known methodological problem for assessment of an-
drogens in PCOS, relatively small study sample size and
lack of any data on roflumilast specific effects on PCOS
treatment outcomes, our observations in both studies so
far do not allow more than a speculation in this regard.
The present study has several limitations. Number of
patients in each treatment group was small, partially at
the expense of the originality of the comparative design
including three treatment arms. The 12-week observa-
tion period was too short to assess the efficacy and
safety of liraglutide and roflumilast as weight loss drugs
in obese women with PCOS. The short-term design was
conducted mainly due to insufficient longer-term safety
data of liraglutide and roflumilast in women that might
still wish to conceive. The importance of lifestyle inter-
vention was introduced at the beginning of the study but
not actively promoted over the course of the study, yet
such setting had the advantage of being similar to the
daily practice. In addition, the open label nature of the
study might be further potential limitation with this re-
gard, as women in the LIRA arm would know they were
given a drug that has been mentioned in the media as an
anti-obesity drug. This could have resulted in a higher
motivation to adhere to the lifestyle intervention. How-
ever, the main strength of this pilot study was the ori-
ginal concept that grasps inclusion of two agents acting
through the GLP-1 axis that had not yet been compared
either in PCOS or any other obese population.
Conclusions
Short-term monotherapy with liraglutide or roflumilast
was superior to metformin in weight loss in obese PCOS
women. Reduction of body weight resulted in improve-
ment of body composition. In addition, liraglutide was
associated with beneficial effects on glucose homeostasis,
whereas roflumilast resulted in total testosterone reduc-
tion and improvement of menstrual frequencies. Consid-
ering the recognized role of incretin system and potential
role of PDE 4 signaling pathways in the pathophysiology
of PCOS further explorations in larger studies of longer
duration are needed to assess the effects of both agents in
this population providing the possible basis for the clinical
approach that could tailor treatment choices to the spe-
cific needs of the patient.
The role of metformin in the management of obesity
remains unsatisfactory. Following recent clinical practice
guidelines metformin should be used in women with PCOSwho are already undergoing lifestyle treatment and do not
have improvement in impaired glucose tolerance or in
those who have normal body weight but still have impaired
glucose tolerance [13]. However, the potential additive
efficacy of novel anti-obesity treatment options targeting
incretin system in combination to metformin should be a
focus of further investigation in PCOS population.
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model assessment; IR: Insulin resistance; COPD: Chronic obstructive
pulmonary disease.
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